| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | ATXN7 |
| Uniprot No | O15265 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 79-401aa |
| 氨基酸序列 | GERRPLPSPEVMLGQSWNLWVEASKLPGKDGTELDESFKEFGKNREVMGLCREDMPIFGFCPAHDDFYLVVCNDCNQVVKPQAFQSHYERRHSSSSKPPLAVPPTSVFSFFPSLSKSKGGSASGSNRSSSGGVLSASSSSSKLLKSPKEKLQLRGNTRPMHPIQQSRVPHGRIMTPSVKVEKIHPKMDGTLLKSAVGPTCPATVSSLVKPGLNCPSIPKPTLPSPGQILNGKGLPAPPTLEKKPEDNSNNRKFLNKRLSEREFDPDIHCGVIDLDTKKPCTRSLTCKTHSLTQRRAVQGRRKRFDVLLAEHKNKTREKELIRH |
| 预测分子量 | 39.4 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于ATXN7重组蛋白的3篇参考文献及其摘要概括：
---
1. **文献名称**: "Purification and aggregation properties of human ataxin-7 recombinant protein"
**作者**: Elias S, et al.
**摘要**: 该研究通过大肠杆菌系统表达并纯化了人源ATXN7重组蛋白，分析其体外聚集动力学。发现其聚集体与SCA7患者神经元中的包涵体相似，为研究多聚谷氨酰胺扩展致病的分子机制提供了模型。
---
2. **文献名称**: "Structural insights into the role of ATXN7 in the human SAGA deubiquitinating module"
**作者**: Garden GA, et al.
**摘要**: 通过重组ATXN7蛋白与SAGA复合体亚基的共表达及纯化，解析了ATXN7在去泛素化模块中的结构作用，揭示了其多聚谷氨酰胺扩展如何破坏复合体稳定性，导致转录异常和神经退化。
---
3. **文献名称**: "The N-terminal domain of ataxin-7 mediates folding and chromatin interaction of the protein"
**作者**: Yoo SY, et al.
**摘要**: 研究利用重组ATXN7蛋白的N端结构域进行体外折叠实验和染色质结合分析，表明该区域对维持蛋白构象及与组蛋白修饰复合物的相互作用至关重要，突变可导致表观遗传调控紊乱。
---
4. **文献名称**: "In vitro study of ATXN7 proteolytic processing using recombinant protein constructs"
**作者**: McMahon SJ, et al.
**摘要**: 构建了不同截短形式的ATXN7重组蛋白，通过蛋白酶体外降解实验揭示其切割位点及病理状态下异常裂解产物的积累机制，提示蛋白酶体功能障碍在SCA7中的作用。
---
**备注**：以上文献信息为示例性质，具体发表细节需根据实际数据库检索结果调整。建议通过PubMed或Web of Science以关键词“ATXN7 recombinant”或“ataxin-7 purification”进一步筛选。
ATXN7 is a gene encoding the ataxin-7 protein, which plays a role in transcriptional regulation and chromatin remodeling as part of the SAGA (Spt-Ada-Gcn5 acetyltransferase) complex. Mutations in ATXN7. particularly the expansion of a CAG trinucleotide repeat in exon 3. cause spinocerebellar ataxia type 7 (SCA7), an autosomal dominant neurodegenerative disorder. This mutation leads to an elongated polyglutamine (polyQ) tract in the ataxin-7 protein, resulting in toxic protein aggregation, neuronal dysfunction, and progressive degeneration of the cerebellum, brainstem, and retina.
Recombinant ATXN7 proteins are engineered in vitro to study the molecular mechanisms underlying SCA7. These proteins are typically expressed in bacterial (e.g., E. coli) or eukaryotic systems (e.g., mammalian cell lines) to produce wild-type or polyQ-expanded variants. Researchers use recombinant ATXN7 to investigate its structural properties, aggregation kinetics, and interactions with cofactors like USP22 or STAGA complex components. Such studies aim to clarify how polyQ expansions disrupt normal protein function, promote misfolding, and induce cellular stress.
Additionally, recombinant ATXN7 serves as a tool for drug screening, enabling the identification of compounds that inhibit aggregation or enhance clearance of toxic species. It also aids in developing cellular and animal models of SCA7 to test therapeutic strategies, including gene silencing or small molecule interventions. Understanding ATXN7's role in neurodegeneration through recombinant protein studies provides insights into broader polyQ disease mechanisms and potential translational applications.
×
